key: cord-0853964-80f0vofm
authors: Ju, Bin; Zheng, Qingbing; Guo, Huimin; Fan, Qing; Li, Tingting; Song, Shuo; Sun, Hui; Shen, Senlin; Zhou, Xinrong; Xue, Wenhui; Cui, Lingyan; Zhou, Bing; Li, Shaowei; Xia, Ningshao; Zhang, Zheng
title: Immune escape by SARS-CoV-2 Omicron variant and structural basis of its effective neutralization by a broad neutralizing human antibody VacW-209
date: 2022-03-08
journal: Cell Res
DOI: 10.1038/s41422-022-00638-6
sha: b33a5fc61d86dd33045dd27ff69311071cad3414
doc_id: 853964
cord_uid: 80f0vofm

nan

Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its variants is still a pandemic raging across the world (Supplementary information, Fig. S1a, b) . A new variant, Omicron, was first detected in South Africa and got dominant in many regions. 1 Omicron has been classified as a variant of concern by the World Health Organization (WHO), whose spike carried more than 30 mutations (Supplementary information, Fig. S1c ). 1, 2 To make a comprehensive evaluation of the susceptibility of Omicron, we summarized plasma samples from 19 convalescent individuals infected with the wild-type (WT) virus, and measured their neutralizing activities against the WT, Beta, Delta, Mu, C.1.2, and Omicron (Supplementary information, Figs. S1d and S2). The Omicron showed more serious resistance to neutralizing antibodies (nAbs) than other variants including Beta and Mu (45.6fold, 9.6-fold, and 15.4-fold, respectively, compared with that against the WT), the latter two of which largely escaped the antibody neutralization prior to the Omicron pandemic. 3, 4 More seriously, some plasma (3/19) lost their neutralizing activities against Omicron (Supplementary information, Fig. S1e ).

To study the mechanism of antibody escape, we analyzed 12 published nAbs binding to the receptor binding domain (RBD) of SARS-CoV-2 with clear structural information. 5, 6 We used these nAbs to mimic the polyclonal antibodies in plasma to explore what kind of nAbs were mostly affected by the mutations. The Omicron decreased or abolished the neutralization and binding affinity of nearly all tested nAbs across Class 1-4 (Supplementary information, Figs. S1f, g, S3, and S4), explaining why Omicron has the most serious antibody evasion. The structural analysis showed that some key mutations were located in or near the footprint of nAbs (Supplementary information, Fig. S5a ). In consistence with previous studies, 1,2,7 K417N and Q493R mainly affect the recognition of Class 1 nAbs to Omicron RBD. Mutations at E484 usually result in complete insensitivity of Class 2 nAbs. For REGN10987, a Class 3 antibody, G446S may diminish the binding of this class of nAbs. The Omicron was the first variant to escape Class 4 nAbs. The structural analysis of H014 showed that S371L may mediate the resistance to this class of nAbs (Supplementary information, Fig. S5b-e) . Fortunately, some minority of existing nAbs are still effective to Omicron. 1,2,7 S309 7 retains effective neutralizing activity and strong binding affinity against Omicron (Supplementary information, Fig. S1f, g) . However, broadly nAbs (bnAbs) are rare and a head-to-head comparison of the structural characterization for the novel bnAb against SARS-CoV-2 variants is lacking.

In this study, we explored bnAbs against Omicron, especially those binding to distinct epitopes away from S309. Previously, we identified nine monoclonal nAbs from individuals immunized with the SARS-CoV-2 inactivated vaccine and measured their crossneutralizing activities against Kappa and Delta. 6 Here, we further evaluated the neutralization of these nAbs against other important variants including Alpha, Beta, Gamma, Mu, Omicron, etc ( Fig. 1a ; Supplementary information, Fig. S6 ). Their neutralizing breadths ranged from 54% (7/13) to 100% (13/13) in the tested SARS-CoV-2 pseudoviruses, and a few of the nAbs (3/9) could still neutralize Omicron. VacW-92 and VacW-120 binding to overlapped epitopes with S309 6 effectively neutralized Omicron (50% inhibitory concentration (IC 50 ) = 1.246 μg/mL and IC 50 = 0.273 μg/ mL, respectively). VacW-209 could neutralize all tested variants with a high potency (geometric IC 50 = 0.063 μg/mL). Meanwhile, the binding affinities of VacW-209 to Mu, C.1.2, and Omicron RBDs may contribute to its broadly neutralizing activity (Supplementary information, Fig. S7 ).

SARS-CoV is closely related to SARS-CoV-2 sharing 80% of amino acid sequence identity in their spike proteins. 8 Therefore, we detected the cross-reaction of VacW-209 to SARS-CoV, which displayed both highly neutralizing activity (IC 50 = 0.141 μg/mL) and binding affinity (K D = 0.540 nM) ( Table S1 ). Three VacW-209 Fabs bind to a completely opened spike with three "up" RBDs. We then performed the focus refinement of regions of Fabbound RBDs of these five structures (Fig. 1h-l) . High-resolution structures revealed that the binding epitope of VacW-209 completely evaded the key RBD mutations in Delta, Mu, C.1.2, and rarely overlapped with mutations in Omicron. The footprints of VacW-209 on WT-RBD and Omicron-RBD are slightly different, and three mutations in Omicron (K417N, S373P, and S375F) are involved in the nAb-RBD interaction (Fig. 1m, n) .

We next analyzed the interaction details of VacW-209 binding to WT and Omicron spikes and revealed that VacW-209 mainly used its long heavy loop at complementarity determining region (HCDR) 3 to mediate spike recognition. In general, longer HCDR3 Letter to the Editor may mediate the recognition of nAbs to target some conserved epitopes, which often reside at strucutually deeper or cryptic regions in viral antigens. 11, 12 The identification of VacW-209 with long HCDR3 partly demonstrated the ability of SARS-CoV-2 inactivated vaccine to induce bnAbs against variants. Besides, the light chain CDR (LCDR) 2 and D34 from LCDR1 are also involved in nAb-RBD interactions (Fig. 1o-r) . For WT-RBD, residues 371, 379, 408, 414, and 415 form an interaction network to VacW-209 containing 11 hydrogen bonds and 2 salt bridges (Fig. 1o, p) . The heavy chain R106 (R106 H ) inserts its long side chain into the pocket formed by RBD aa. 371-385, which contains three key mutations of Omicron (S371L/S373P/S375F) (Supplementary information, Fig. S14a-c) . Although VacW-209 showed a decreased neutralization against Omicron (Fig. 1a) , our structural analysis showed that the mutations surrounding aa. 371-385 loop seemed not to obviously affect the binding of VacW-209 since the S373P and S375F build three new hydrogen bonds with R106 H (Fig. 1q) . Other Omicron mutations are not involved in the hydrogen bond interactions, and there are a total of 12 hydrogen bonds and 1 salt bridges formed (Fig. 1q, r) , which are comparable to that in WT. We further found that the binding of VacW The similar binding mode of VacW-209 was also found in some previously reported nAbs including C118, C022, S2X35, and S2X259 [13] [14] [15] (Fig. 1s) . Available structural information revealed that the aforementioned four nAbs and VacW-209 shared lots of epitope residues located in conserved RBD aa. 376-385 and 405-416, while with diverse coverage of key mutations of Omicron ( Fig. 1t; Supplementary information, Fig. S16a-e) . Of these mutations, S371L, S373P, S375F, K417N, N501Y, and Y505H were structurally close to or involved in the binding epitopes of VacW-209-like nAbs. In the head-to-head comparison, although C022 and S2X35 showed significant reductions of neutralization against Omicron, these VacW-209-like nAbs generally maintained effectively neutralizing and binding activities to various SARS-CoV-2 variants and even SARS-CoV (Supplementary information, Fig. S16f , g and S17). The molecular mechanism underlying why these similar nAbs display diverse neutralizing activities need to be elucidated in the future.

In conclusion, VacW-209 identifies a highly conserved epitope on the RBDs among SARS-CoV-2 variants overlapping with the ACE2-binding site, which explains its potent neutralization. VacW-209 could strongly compete with Class 4 nAbs, indicating the potential cross-neutralization against sarbecoviruses. These VacW-209-like nAbs shared a similar antibody response to both SARS-CoV-2 and SARS-CoV, highlighting a key target for the universal vaccine design. As this binding epitope is highly conversed in different variants, vaccine design pursuant to this epitope feature may induce more bnAbs and benefit for the development of broad-spectrum COVID-19 vaccines. VacW-209, alone or in combination with S309, could also be used as countermeasure against SARS-CoV-2 variants including Omicron and even other forthcoming sarbecoviruses in the future.

Bin Ju 1,2,6 ✉ , Qingbing Zheng 3,4,6 , Huimin Guo 1,6 , Qing Fan 1,6 , Tingting Li 3,4,6 , Shuo Song 1,6 , Hui Sun 3,4,6 , Senlin Shen 1 , Xinrong Zhou 1 , Wenhui Xue 3,4 , Lingyan Cui 3,4 , Bing Zhou 1 , Shaowei Li 3,4 ✉ , Ningshao Xia 3,4 ✉ and Zheng Zhang 1,2,5 ✉

the Shenzhen Science and Technology Program (RCYX20200714114700046), and the Science and Technology Innovation Committee of Shenzhen Municipality (JSGG20200207155251653, JSGG20200807171401008, KQTD20200909113758004, JCYJ20190809115617365, JSGG20210901145200002)

AUTHOR CONTRIBUTIONS

conceived and designed the study

X.Z., W.X., L.C., and B.Z. Z.Z., N.X., S.L., B.J., and Q.Z. participated in discussion of the results and wrote the paper. All authors read and approved this version of paper.

The authors declare no competing interests.

Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41422-022-00638-6.Correspondence and requests for materials should be addressed to Bin Ju, Shaowei Li, Ningshao Xia or Zheng Zhang.Reprints and permission information is available at http://www.nature.com/reprints